OBJECTIVES: An objective of the INSTIGATE study is to describe clinical and patient reported outcomes after 6 months of insulin therapy in patients with type 2 diabetes. This abstract presents data from patients enrolled in Germany and UK. METHODS: INSTIGATE is an ongoing prospective European observational study investigating patients with type 2 diabetes who initiated insulin during usual care. Data on outcomes were collected at baseline and at 3 and 6 months following insulin initiation. RESULTS: A total of 509 patients were enrolled in Germany and UK. Six-month follow-up data was collected from 457 patients. Clinical outcomes, mean (SD), changed from baseline to six months post insulin initiation as follows: FBG improved from 11.5 (4.7) mmol/l to 6.9 (1.8) mmol/l in Germany and from 13.3 (4.9) mmol/l to 10.2 (4.3) mmol/l in UK. HbA1c improved from 9.2 (2.0)% to 6.9 (1.0)% in Germany and from 10.2 (1.7)% to 8.4 (1.4)% in UK. BMI increased from 30.5 (6.0) kg/m2 to 31.0 (5.9) kg/m2 in Germany and from 31.9 (6.6) kg/m2 to 32.5 (5.6) kg/m2 in UK. Improvements were seen in health status using the EQ-5D; in Germany the median visual analogue scale score increased from 70 to 79 and in UK from 65 to 70. The number of patients self-reporting hypoglycaemic episodes increased as follows for German and UK patients respectively; in the 3 months before insulin initiation 9 (3.5%) and 13 (5.1%) patients experienced a total of 31 episodes in each country, and in the 3 months before the six-month follow-up visit 26 (11.2%) and 57 (25.4%) patients experienced a total of 153 and 221 episodes. CONCLUSION: Differences in baseline characteristics and initial insulin regimes prescribed in UK and German patients were observed. Glycaemic control and health-related quality-of-life improved in the 6 months following insulin initiation. However BMI and rates of hypoglycaemia increased.